Similar articles

• Recent developments in de novo design and scaffold hopping.

  Mauser H, Guba W. Mauser H, et al. Curr Opin Drug Discov Devel. 2008 May;11(3):365-74. Curr Opin Drug Discov Devel. 2008. PMID: 18428090 Review.
• Concept of combinatorial de novo design of drug-like molecules by particle swarm optimization.

  Hartenfeller M, Proschak E, Schüller A, Schneider G. Hartenfeller M, et al. Chem Biol Drug Des. 2008 Jul;72(1):16-26. doi: 10.1111/j.1747-0285.2008.00672.x. Epub 2008 Jun 13. Chem Biol Drug Des. 2008. PMID: 18564216
• Tagged fragment method for evolutionary structure-based de novo lead generation and optimization.

  Liu Q, Masek B, Smith K, Smith J. Liu Q, et al. J Med Chem. 2007 Nov 1;50(22):5392-402. doi: 10.1021/jm070750k. Epub 2007 Oct 6. J Med Chem. 2007. PMID: 17918924
• The use of ligand-based de novo design for scaffold hopping and sidechain optimization: two case studies.

  Feher M, Gao Y, Baber JC, Shirley WA, Saunders J. Feher M, et al. Bioorg Med Chem. 2008 Jan 1;16(1):422-7. doi: 10.1016/j.bmc.2007.09.026. Epub 2007 Sep 18. Bioorg Med Chem. 2008. PMID: 17920281
• Importance of molecular computer modeling in anticancer drug development.

  Geromichalos GD. Geromichalos GD. J BUON. 2007 Sep;12 Suppl 1:S101-18. J BUON. 2007. PMID: 17935268 Review.